Fondazione Toscana Gabriele Monasterio

Running trials

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  Pharmacological optimization in prevention in Heart Failure: A Sex-gap?

  2025-520660-18-00· Phase 4· Policlinico San Donato S.p.A.· Source

• Recruiting

  Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?

  NCT07295522· Phase 4· IRCCS Policlinico S. Donato· Source

• Recruiting

  A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

  NCT07298044· Phase 4· Bayer· Source

• Recruiting

  A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

  2024-515125-28-00· Phase 2· Imbria Pharmaceuticals Inc.· Source

• Recruiting

  ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

  NCT07218887· Phase 1/2· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

  NCT05974462· Phase 3· University Hospital, Antwerp· Source

• Active, not recruiting

  A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease

  2023-506971-89-00· Phase 3· Syn2bio S.A.· Source

• Active, not recruiting

  LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

  NCT05983250· Phase 3· Tenax Therapeutics, Inc.· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Recruiting

  Effect of dapagliflozin on the quality of life and exercise capacity of patients with amyloid transthyretin cardiac amyloidosis: a pilot, phase 2b study

  2023-504041-31-00· Phase 2· Fondazione Toscana Gabriele Monasterio· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) to non-invasively diagnose cardiac AL amyloidosis: the PETAL study.

  2024-517942-33-03· Phase 3· Fondazione Toscana Gabriele Monasterio· Source

• Recruiting

  ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing

  NCT06324682· University Hospital of Ferrara· Source

• Recruiting

  Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

  NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source

• Recruiting

  COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

  NCT05633810· Phase 3· Montreal Heart Institute· Source

• Recruiting

  Italian Anderson Fabry Disease Cardiovascular Registry

  NCT06806813· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source

• Recruiting

  Comparison between single and dual therapy with drugs that inhibits platelet aggregation in patient undergoing the percutaneous left atrial appenDAge closure (ARMYDA-AMULET in which people will be allocated by chance to receive two different options of treatment and which will involves different clinical sites)

  2024-515361-34-00· Phase 4· Fondazione Toscana Gabriele Monasterio· Source

• Recruiting

  MYTHS - MYocarditis THerapy With Steroids

  NCT05150704· Phase 3· Niguarda Hospital· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Cytokinetics· Source

• Active, not recruiting

  CHAMPION-AF Clinical Trial

  NCT04394546· Boston Scientific Corporation· Source

• Active, not recruiting

  Amplatzer Amulet LAAO vs. NOAC

  NCT04226547· Abbott Medical Devices· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Actelion· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis7 recruiting
• Heart failure5 recruiting
• Atrial fibrillation3 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Myocarditis2 recruiting
• Coronary artery disease1 recruiting
• Dilated cardiomyopathy1 recruiting
• Fabry disease1 recruiting
• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Type 2 diabetes1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  The GLACE Study: Evaluating CLAAS With ICE Guided LAA Closure

  NCT06580275· Conformal Medical, Inc· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Active, not recruiting

  Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT06122779· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis

  2024-517971-19-01· Phase 2· Fondazione Toscana Gabriele Monasterio· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

  NCT05442047· Phase 2· Novo Nordisk A/S· Source

• Completed

  Randomized Double-blind Trial to Study the Benefit of Colchicine in Patients With Acutely Decompensated Heart Failure

  NCT04705987· Phase 3· Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  Comparison of CRT-D and CRT-DX Systems (CRT-NEXT)

  NCT03587064· Associazione Portatori Dispositivi Impiantabili Cardiaci· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Boston Scientific Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Amyloidosis50 works · 10 trials
• Hypertrophic cardiomyopathy19 works · 5 trials
• Thalassaemia16 works · 0 trials
• Pulmonary arterial hypertension10 works · 3 trials
• Dilated cardiomyopathy9 works · 1 trial
• Familial hypercholesterolaemia6 works · 0 trials